213 related articles for article (PubMed ID: 28356989)
1. Sorafenib therapy following resection prolongs disease-free survival in patients with advanced hepatocellular carcinoma at a high risk of recurrence.
Liao Y; Zheng Y; He W; Li Q; Shen J; Hong J; Zou R; Qiu J; Li B; Yuan Y
Oncol Lett; 2017 Feb; 13(2):984-992. PubMed ID: 28356989
[TBL] [Abstract][Full Text] [Related]
2. Advanced hepatocellular carcinoma: A regional cancer center experience of 48 cases.
Lokesh KN; Chaudhuri T; Lakshmaiah KC; Babu KG; Dasappa L; Jacob LA; Suresh Babu MC; Rudresha AH; Rajeev LK
Indian J Cancer; 2017; 54(3):526-529. PubMed ID: 29798951
[TBL] [Abstract][Full Text] [Related]
3. Hepatocellular carcinoma cases with high levels of c-Raf-1 expression may benefit from postoperative adjuvant sorafenib after hepatic resection even with high risk of recurrence.
Lei J; Zhong J; Hao J; Liu Z; Zhang P; Wu L; Yan L; Zhu J; Zeng Y; Li B; Wen T; Wang W
Oncotarget; 2016 Jul; 7(27):42598-42607. PubMed ID: 26981887
[TBL] [Abstract][Full Text] [Related]
4. Sorafenib after resection improves the outcome of BCLC stage C hepatocellular carcinoma.
Li J; Hou Y; Cai XB; Liu B
World J Gastroenterol; 2016 Apr; 22(15):4034-40. PubMed ID: 27099447
[TBL] [Abstract][Full Text] [Related]
5. Comparison of different adjuvant therapy regimen efficacies in patients with high risk of recurrence after radical resection of hepatocellular carcinoma.
Feng X; Feng GY; Tao J; Ao YP; Wu XH; Qi SG; Shi ZR
J Cancer Res Clin Oncol; 2023 Sep; 149(12):10505-10518. PubMed ID: 37284841
[TBL] [Abstract][Full Text] [Related]
6. Survival outcomes of hepatic resection compared with transarterial chemoembolization or sorafenib for hepatocellular carcinoma with portal vein tumor thrombosis.
Lee JM; Jang BK; Lee YJ; Choi WY; Choi SM; Chung WJ; Hwang JS; Kang KJ; Kim YH; Chauhan AK; Park SY; Tak WY; Kweon YO; Kim BS; Lee CH
Clin Mol Hepatol; 2016 Mar; 22(1):160-7. PubMed ID: 27044767
[TBL] [Abstract][Full Text] [Related]
7. Sorafenib With and Without Transarterial Chemoembolization for Advanced Hepatocellular Carcinoma With Main Portal Vein Tumor Thrombosis: A Retrospective Analysis.
Zhang Y; Fan W; Wang Y; Lu L; Fu S; Yang J; Huang Y; Yao W; Li J
Oncologist; 2015 Dec; 20(12):1417-24. PubMed ID: 26446238
[TBL] [Abstract][Full Text] [Related]
8. Comparative Efficacy of Cabozantinib and Regorafenib for Advanced Hepatocellular Carcinoma.
Kelley RK; Mollon P; Blanc JF; Daniele B; Yau T; Cheng AL; Valcheva V; Marteau F; Guerra I; Abou-Alfa GK
Adv Ther; 2020 Jun; 37(6):2678-2695. PubMed ID: 32424805
[TBL] [Abstract][Full Text] [Related]
9. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Zhu AX; Kang YK; Yen CJ; Finn RS; Galle PR; Llovet JM; Assenat E; Brandi G; Pracht M; Lim HY; Rau KM; Motomura K; Ohno I; Merle P; Daniele B; Shin DB; Gerken G; Borg C; Hiriart JB; Okusaka T; Morimoto M; Hsu Y; Abada PB; Kudo M;
Lancet Oncol; 2019 Feb; 20(2):282-296. PubMed ID: 30665869
[TBL] [Abstract][Full Text] [Related]
10. Prognostic factors in patients with advanced hepatocellular carcinoma treated with sorafenib.
Pinter M; Sieghart W; Hucke F; Graziadei I; Vogel W; Maieron A; Königsberg R; Weissmann A; Kornek G; Matejka J; Stauber R; Buder R; Grünberger B; Schöniger-Hekele M; Müller C; Peck-Radosavljevic M
Aliment Pharmacol Ther; 2011 Oct; 34(8):949-59. PubMed ID: 21883324
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of Sorafenib for the Treatment of Post-Transplant Hepatocellular Carcinoma Recurrence.
Kang SH; Cho H; Cho EJ; Lee JH; Yu SJ; Kim YJ; Yi NJ; Lee KW; Suh KS; Yoon JH
J Korean Med Sci; 2018 Nov; 33(45):e283. PubMed ID: 30402048
[TBL] [Abstract][Full Text] [Related]
12. Survival Benefit of Experience of Liver Resection for Advanced Recurrent Hepatocellular Carcinoma Treated with Sorafenib: A Propensity Score Matching Analysis.
Hsueh KC; Lee CC; Huang PT; Liang CY; Yang SF
Curr Oncol; 2023 Mar; 30(3):3206-3216. PubMed ID: 36975456
[TBL] [Abstract][Full Text] [Related]
13. Indicators of sorafenib efficacy in patients with advanced hepatocellular carcinoma.
Yada M; Masumoto A; Motomura K; Tajiri H; Morita Y; Suzuki H; Senju T; Koyanagi T
World J Gastroenterol; 2014 Sep; 20(35):12581-7. PubMed ID: 25253961
[TBL] [Abstract][Full Text] [Related]
14. Association Between Adjuvant Sorafenib and the Prognosis of Patients With Hepatocellular Carcinoma at a High Risk of Recurrence After Radical Resection.
Li Q; Song T
Front Oncol; 2021; 11():633033. PubMed ID: 34631511
[TBL] [Abstract][Full Text] [Related]
15. Adjuvant sorafenib after heptectomy for Barcelona Clinic Liver Cancer-stage C hepatocellular carcinoma patients.
Xia F; Wu LL; Lau WY; Huan HB; Wen XD; Ma KS; Li XW; Bie P
World J Gastroenterol; 2016 Jun; 22(23):5384-92. PubMed ID: 27340354
[TBL] [Abstract][Full Text] [Related]
16. Metronomic capecitabine as second-line treatment for hepatocellular carcinoma after sorafenib discontinuation.
Trevisani F; Brandi G; Garuti F; Barbera MA; Tortora R; Casadei Gardini A; Granito A; Tovoli F; De Lorenzo S; Inghilesi AL; Foschi FG; Bernardi M; Marra F; Sacco R; Di Costanzo GG
J Cancer Res Clin Oncol; 2018 Feb; 144(2):403-414. PubMed ID: 29249005
[TBL] [Abstract][Full Text] [Related]
17. Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial.
Kelley RK; Rimassa L; Cheng AL; Kaseb A; Qin S; Zhu AX; Chan SL; Melkadze T; Sukeepaisarnjaroen W; Breder V; Verset G; Gane E; Borbath I; Rangel JDG; Ryoo BY; Makharadze T; Merle P; Benzaghou F; Banerjee K; Hazra S; Fawcett J; Yau T
Lancet Oncol; 2022 Aug; 23(8):995-1008. PubMed ID: 35798016
[TBL] [Abstract][Full Text] [Related]
18. Recurrence-free survival of a hepatocellular carcinoma patient with tumor thrombosis of the inferior vena cava after treatment with sorafenib and hepatic resection.
Nakamura K; Beppu T; Hayashi H; Okabe H; Imai K; Nitta H; Chikamoto A; Ishiko T; Sasaki M; Baba H
Int Surg; 2015 May; 100(5):908-14. PubMed ID: 26011214
[TBL] [Abstract][Full Text] [Related]
19. Role of Sorafenib in Patients With Recurrent Hepatocellular Carcinoma After Liver Transplantation.
de'Angelis N; Landi F; Nencioni M; Palen A; Lahat E; Salloum C; Compagnon P; Lim C; Costentin C; Calderaro J; Luciani A; Feray C; Azoulay D
Prog Transplant; 2016 Dec; 26(4):348-355. PubMed ID: 27555074
[TBL] [Abstract][Full Text] [Related]
20. Barcelona clinic liver cancer-stage C hepatocellular carcinoma: A novel approach to subclassification and treatment.
Jun CH; Yoon JH; Cho E; Shin SS; Cho SB; Kim HJ; Park CH; Kim HS; Choi SK; Rew JS
Medicine (Baltimore); 2017 Apr; 96(17):e6745. PubMed ID: 28445298
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
